Pharmacology of Mood Stabilizers

Introduction/Overview

Mood stabilizers constitute a cornerstone of management for affective disorders, particularly bipolar disorder. Their therapeutic repertoire extends to episodes of mania, depression, and certain psychotic states. The clinical relevance of mood stabilizers is underscored by their ability to mitigate relapse rates, reduce suicidality, and improve overall functional outcomes. A systematic understanding of their pharmacology is imperative for clinicians, pharmacists, and researchers engaged in psychopharmacology and medication therapy management.

Learning objectives for this monograph include:

• Identify the primary pharmacologic classes of mood stabilizers and their chemical frameworks.
• Articulate the principal mechanisms of action underlying therapeutic efficacy and adverse event profiles.
• Describe key pharmacokinetic parameters influencing dosing strategies and therapeutic monitoring.
• Recognize approved indications, off‑label applications, and clinical scenarios necessitating cautious use.
• Appraise drug–drug interactions, special population considerations, and safety monitoring requirements.

Classification

Drug Classes and Categories

Mood stabilizers are conventionally grouped into two major pharmacologic categories:

• Classical mood stabilizer: Lithium, distinguished by its narrow therapeutic index and unique neurochemical profile.
• Anticonvulsant mood stabilizers: A diverse cohort including valproate, carbamazepine, lamotrigine, oxcarbazepine, and topiramate. These agents share anticonvulsant properties but exhibit distinct mechanisms of mood regulation.

Chemical Classification

From a chemical standpoint, lithium is an alkali metal ion with minimal organic structure. Anticonvulsant mood stabilizers are predominantly heterocyclic compounds or derivatives thereof. Valproate is a branched short-chain fatty acid; carbamazepine and oxcarbazepine are dibenzazepine derivatives; lamotrigine is a 2-aminopyrimidine; topiramate contains a sulfonamide moiety. Structural diversity contributes to variations in receptor affinity, transporter interactions, and metabolic pathways.

Mechanism of Action

Detailed Pharmacodynamics

Precise mechanisms remain incompletely elucidated; however, several consensus pathways have emerged.

Lithium

Lithium’s therapeutic actions are ascribed to modulation of second messenger systems. It inhibits glycogen synthase kinase‑3β (GSK‑3β), thereby enhancing phosphatidylinositol‑3‑kinase signaling. Lithium also antagonizes inositol monophosphatase, leading to decreased phosphatidylinositol‑3,4,5‑trisphosphate turnover. These alterations influence neuronal plasticity, neurotransmitter release, and neuroprotection.

Anticonvulsant Mood Stabilizers

Valproate primarily enhances gamma‑aminobutyric acid (GABA) neurotransmission by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, increasing intracellular GABA levels. Additionally, it modulates voltage‑gated sodium channels, attenuating neuronal hyperexcitability.

Carbamazepine and oxcarbazepine exert rapid blockade of voltage‑gated sodium channels, stabilizing the inactive state and reducing repetitive firing. Lamotrigine suppresses glutamate release by inhibiting voltage‑dependent sodium channels and reducing presynaptic calcium influx, thereby limiting excitatory neurotransmission.

Topiramate’s multifaceted actions include enhancement of GABAergic inhibition, blockade of AMPA/kainate glutamate receptors, and inhibition of carbonic anhydrase. These combined effects dampen excitatory drive and contribute to mood regulation.

Receptor Interactions

Lithium demonstrates low affinity for classical neurotransmitter receptors but exerts modulatory effects on dopaminergic, serotonergic, and glutamatergic systems indirectly. Anticonvulsants may bind to specific subunits of ligand‑gated ion channels (e.g., GABA_A, NMDA) or influence receptor trafficking and post‑synaptic density. For example, lamotrigine increases the expression of GABA_A receptor subunits, potentially augmenting inhibitory tone.

Molecular/Cellular Mechanisms

Beyond receptor modulation, mood stabilizers influence intracellular signaling cascades, gene expression, and neurotrophic factors. Lithium upregulates brain‑derived neurotrophic factor (BDNF) and promotes neurogenesis. Anticonvulsants stimulate the synthesis of fatty acids and phospholipids, supporting membrane integrity and synaptic function. Consequently, the therapeutic benefits may derive from a confluence of neurotransmission modulation, neuroprotection, and neuroplasticity enhancement.

Pharmacokinetics

Absorption

Lithium is absorbed rapidly from the gastrointestinal tract, with bioavailability approaching 100 % when administered orally. Peak plasma concentrations (C_max) are typically achieved within 1–2 h. Valproate exhibits high oral bioavailability (≈ 90 %) and reaches C_max in 1–5 h. Carbamazepine and oxcarbazepine demonstrate moderate absorption (≈ 70 %–80 %) with C_max at 2–4 h. Lamotrigine shows 100 % bioavailability, with C_max after 1–2 h. Topiramate is absorbed efficiently (≈ 100 %) and reaches peak levels within 2–4 h.

Distribution

All mood stabilizers are widely distributed throughout body tissues. Lithium penetrates the central nervous system (CNS) readily, with CSF concentrations approximating 70–80 % of plasma levels. Valproate is highly protein‑bound (≈ 90 %), largely to albumin. Carbamazepine binds extensively to plasma proteins, with a binding fraction of 70–80 %. Lamotrigine also displays substantial protein binding (≈ 90 %). Topiramate’s protein binding is moderate (≈ 30 %) and may be competitively displaced by other highly bound drugs.

Metabolism

Metabolic pathways differ markedly among agents. Lithium is excreted unchanged; hepatic metabolism is negligible. Valproate undergoes glucuronidation, β‑oxidation, and mitochondrial β‑oxidation. Carbamazepine is metabolized by hepatic cytochrome P450 (CYP3A4) to the active metabolite carbamazepine‑10,11‑epoxide; subsequent conjugation via epoxide hydrolase and glucuronidation facilitates excretion. Oxcarbazepine is rapidly converted to the active thiohydroxamic acid metabolite (MESNA) and then to the inactive inactive metabolite (MHD). Lamotrigine is metabolized via glucuronidation (UGT1A4) and to a lesser extent by CYP3A4. Topiramate is largely excreted unchanged; hepatic metabolism is minimal, involving glucuronidation and oxidation.

Excretion

Renal excretion predominates for lithium, valproate, carbamazepine metabolites, lamotrigine, and topiramate. The glomerular filtration rate (GFR) significantly influences plasma concentrations, particularly for lithium and lamotrigine. Clearance of valproate is reduced in hepatic impairment, while carbamazepine clearance may be altered by hepatic enzyme induction or inhibition. Topiramate clearance is minimally affected by hepatic dysfunction but requires adjustment in severe renal impairment.

Half‑life and Dosing Considerations

The terminal elimination half‑life (t_1/2) for lithium ranges from 20–24 h. Valproate’s t_1/2 is 9–12 h; carbamazepine’s is 12–13 h; oxcarbazepine’s is 5–6 h; lamotrigine’s is 25–30 h; topiramate’s is 20 h. Dosing schedules should reflect these kinetics: once‑daily regimes are typical for valproate and carbamazepine; twice‑daily regimens are common for lithium and lamotrigine to maintain steady‑state levels. Therapeutic drug monitoring (TDM) is advisable for lithium, valproate, carbamazepine, lamotrigine, and topiramate due to variable pharmacokinetics and narrow therapeutic windows.

Therapeutic Uses/Clinical Applications

Approved Indications

• Lithium: Bipolar I disorder (manic and mixed episodes), augmentation in major depressive disorder, prophylaxis of relapse.
• Valproate: Bipolar disorder (mania and mixed episodes), adjunctive therapy for refractory depression, seizure control in comorbid epilepsy.
• Carbamazepine: Bipolar disorder (mania), trigeminal neuralgia, seizure disorders.
• Lamotrigine: Bipolar disorder (maintenance phase), adjunctive therapy for depression.
• Oxcarbazepine: Bipolar disorder (mania), seizure disorders.
• Topiramate: Adjunctive therapy for bipolar depression, weight management in metabolic syndrome, seizure control.

Common Off‑Label Uses

Off‑label indications include the use of lithium in borderline personality disorder, augmentation in schizophrenia, and prophylaxis in seasonal affective disorder. Valproate and carbamazepine are employed for mood stabilization in schizoaffective disorder, and lamotrigine is occasionally used in treatment‑resistant depression. Topiramate has been investigated for alcohol dependence and binge eating disorders.

Adverse Effects

Common Side Effects

• Lithium: tremor, polyuria, polydipsia, nausea, mild cognitive dulling, weight gain.
• Valproate: nausea, tremor, weight gain, alopecia, embryogenic risk, hematologic suppression.
• Carbamazepine: dizziness, ataxia, nausea, hyponatremia, rash (SJS/TEN risk).
• Lamotrigine: skin rash, including Stevens–Johnson syndrome, mild rash in 10 % of patients.
• Oxcarbazepine: hyponatremia, dizziness, ataxia, rash.
• Topiramate: paresthesia, cognitive slowing, weight loss, kidney stones, metabolic acidosis.

Serious/Rare Adverse Reactions

Serious complications encompass lithium toxicity (neurotoxicity, nephrogenic diabetes insipidus), valproate‑induced hepatotoxicity, carbamazepine‑induced hematologic abnormalities (aplastic anemia), lamotrigine‑induced Stevens–Johnson syndrome, and topiramate‑induced metabolic derangements (type II metabolic acidosis). Early recognition of warning signs and prompt dose adjustment are critical.

Black Box Warnings

Lithium carries a black box warning for potential nephrogenic diabetes insipidus, cardiac conduction abnormalities, and pregnancy‑associated fetal risk (Ebstein anomaly). Valproate’s warning addresses teratogenicity, particularly neural tube defects, and hepatic dysfunction. Lamotrigine’s warning emphasizes rash risk, including Stevens–Johnson syndrome. Topiramate’s warning highlights risk of cognitive impairment and metabolic acidosis.

Drug Interactions

Major Drug–Drug Interactions

• Lithium: Antidiuretic hormone antagonists, ACE inhibitors, diuretics (thiazides, loop), NSAIDs, and beta‑blockers can elevate lithium levels. Concomitant use of carbamazepine and valproate may alter lithium clearance.
• Valproate: CYP3A4 inducers (rifampin, carbamazepine) reduce valproate levels; inhibitors (ketoconazole) increase levels. Valproate competes with other drugs for glucuronidation pathways (e.g., phenytoin).
• Carbamazepine: Induces CYP3A4, reducing plasma concentrations of oral contraceptives, warfarin, and other CYP3A4 substrates. Requires dose adjustment of concomitant medications.
• Lamotrigine: N,N‑diethyl‑p‑hydroxylamine (DEHA) from carbamazepine and phenobarbital reduces lamotrigine clearance. Concurrent use with valproate increases lamotrigine levels, necessitating dose reduction.
• Topiramate: Competitive inhibition of topiramate metabolism can occur with drugs that induce CYP2C19 (e.g., rifampin). Concurrent use with other CNS depressants may potentiate sedation.

Contraindications

Absolute contraindications include severe renal impairment (e.g., estimated GFR < 30 mL/min) for lithium and lamotrigine; pregnancy for valproate; severe hepatic dysfunction for valproate and carbamazepine; known hypersensitivity to any component. Relative contraindications involve concurrent use of medications with overlapping toxicity profiles, such as multiple sodium channel blockers.

Special Considerations

Use in Pregnancy/Lactation

Lithium: Category D; fetal risk (Ebstein anomaly) is dose‑dependent. Dose reduction or discontinuation is recommended if possible.
Valproate: Category X; teratogenic risk is significant; alternative agents should be considered.
Carbamazepine: Category C; risk of neural tube defects; consider alternative.
Lamotrigine: Category C; risk of cleft palate; careful monitoring.
Topiramate: Category C; limited data; risk of fetal growth restriction.

Lactation: Lithium and carbamazepine excrete into breast milk; caution advised. Valproate and lamotrigine have lower transfer rates but still warrant monitoring. Topiramate levels in milk are minimal; however, infant neurodevelopment should be monitored.

Pediatric/Geriatric Considerations

In pediatric populations, dosing must account for developmental pharmacokinetics; therapeutic drug monitoring is essential for lithium and lamotrigine. Geriatric patients often exhibit reduced hepatic and renal clearance; dose adjustments and monitoring for cognitive effects are recommended. Age‑related changes in plasma protein binding may alter free drug concentrations.

Renal/Hepatic Impairment

Renal impairment: Lithium requires dose reduction and serum level monitoring. Lamotrigine clearance decreases proportionally to GFR; dose adjustment is necessary.
Hepatic impairment: Valproate metabolism is substantially reduced; serum levels may rise. Carbamazepine metabolism is also hepatic; caution with severe liver disease. Topiramate metabolism is modestly hepatic; liver function should be monitored but dose adjustment is generally unnecessary for mild–moderate hepatic impairment.

Summary/Key Points

• Three principal classes of mood stabilizers exist: lithium, anticonvulsants, and newer agents (topiramate).
• Mechanisms involve modulation of ion channels, neurotransmitter systems, and intracellular signaling pathways.
• Pharmacokinetics vary substantially; therapeutic drug monitoring is advised for most agents.
• Clinical indications span bipolar disorder, adjunctive depression therapy, and seizure control.
• Adverse effect profiles necessitate vigilant monitoring for toxicity, especially in vulnerable populations.
• Drug interactions are frequent; dose adjustments and monitoring are essential.
• Special considerations include pregnancy, lactation, renal/hepatic impairment, and age‑related pharmacokinetic changes.
• Cautionary use of lithium and valproate in pregnancy due to teratogenic risk.
• Lamotrigine and carbamazepine require careful monitoring for rash and hematologic toxicity, respectively.
• Topiramate offers benefits in weight management and metabolic syndrome but carries a risk of metabolic acidosis.

Incorporating these pharmacologic principles into clinical practice may enhance therapeutic outcomes, reduce adverse events, and promote individualized patient care in the management of affective disorders.

References

1. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.